Metastatic HSPC: ASCO GU 2026 Treatment Advances

The treatment landscape for metastatic hormone-sensitive prostate cancer (HSPC) is undergoing a critical reassessment, moving beyond simply adding more intensive therapies to…

Source link

Leave a Comment